Supernus Pharmaceuticals vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Supernus Pharmaceuticals Inc (SUPN)

Q3 202623 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

July 202623 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

Latest23 Jun – 20 Aug 2026

▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.
The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.
Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.
The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

August 202620 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest20 Jul – 25 Sep 2026

▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.
This is the period's dominant new event and the main reason ACAD moved.
Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.
It is the main new positive force supporting ACAD's price this period.
Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.
Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.
Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.
Explains the regulatory and demand backdrop behind the remlifanserin story.